Compliance with Guideline-Directed Medical Therapy and Early Implantable Cardioverter-Defibrillator Activation in Heart Failure: A Retrospective Study

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39076952

Authors

Ivan Prepolec

Vedran Pasara

Andrija Nekic

Jakov Emanuel Bogdanic

Jurica Putric Posavec

Borka Pezo Nikolic

Miroslav Krpan

Richard Matasic

Mislav Puljevic

Martina Lovric Bencic

Davor Puljevic

Davor Milicic

Carlo de Asmundis

Gian Battista Chierchia

Giacomo Mugnai

Vedran Velagic

Affiliations

Soon will be listed here.

Abstract

Background: This study was conducted to evaluate compliance with guideline-directed optimal medical therapy (OMT) and its association with early implantable cardioverter-defibrillator (ICD) activation in patients with heart failure and reduced ejection fraction (HFrEF).

Methods: Retrospective data from 307 patients who underwent ICD implantation for primary prevention from 2011 to 2017 were collected and analyzed.

Results: Among the study participants, only 23.8% received the maximum tolerated dose of OMT prior to ICD implantation, with 59.0% receiving all three OMT medication groups. No significant difference in OMT compliance was found between patients with ischemic cardiomyopathy (ICM) and those with non-ischemic dilated cardiomyopathy (DCM). However, DCM patients received ICDs more frequently at the time of diagnosis than ICM patients (13.8% vs. 0.7%). Early ICD activation (within 3 months) occurred in only one patient who had not received appropriate OMT, representing 0.7% of all ICM patients. Furthermore, early activation was also infrequent in patients who received OMT (2.9% of ICM patients and 2.6% of DCM patients). Echocardiography follow-up data revealed that 20.4% of ICM patients and 29.8% of DCM patients who did not receive OMT before ICD implantation showed improvement in the left ventricular ejection fraction (EF) to 35% or more.

Conclusions: This study found suboptimal compliance with OMT prior to ICD implantation in HFrEF patients. The results showed that early ICD activation was rare in all patient groups, especially those who did not receive the prescribed 3 months of OMT. More research is needed to investigate longer waiting periods for the evaluation of potential EF improvement, and to better evaluate the eligibility of HFrEF patients for ICD. The current findings have potential implications for clinical practice and patient outcomes.

References

McNamara D, Starling R, Cooper L, Boehmer J, Mather P, Janosko K . Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol. 2011; 58(11):1112-8. PMC: 6467576. DOI: 10.1016/j.jacc.2011.05.033. View

Waezsada E, Hutter J, Kahle P, Yogarajah J, Sperzel J, Kuniss M . Guideline Directed Medical Therapy at Discharge and Further Uptitration Leading to Reduction in Indication for Prophylactic ICD Implantation during Protected Waiting Period. J Clin Med. 2022; 11(20). PMC: 9605665. DOI: 10.3390/jcm11206122. View

Zecchin M, Merlo M, Pivetta A, Barbati G, Lutman C, Gregori D . How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?". Am J Cardiol. 2011; 109(5):729-35. DOI: 10.1016/j.amjcard.2011.10.033. View

Mehta N, Abdulsalam N, Kouides R, Ahmed H, Atif R, Shah A . Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators. Clin Cardiol. 2019; 43(3):260-266. PMC: 7068066. DOI: 10.1002/clc.23295. View

Zipes D, Borggrefe M, Buxton A, Chaitman B, Fromer M, Gregoratos G . ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of.... Europace. 2006; 8(9):746-837. DOI: 10.1093/europace/eul108. View

Anagnostopoulos I, Kousta M, Kossyvakis C, Lakka E, Paraskevaidis N, Schizas N . The prognostic role of late gadolinium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter defibrillators for primary prevention. A systematic review and.... J Interv Card Electrophysiol. 2021; 63(3):523-530. DOI: 10.1007/s10840-021-01027-6. View

Priori S, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J . 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the.... Eur Heart J. 2015; 36(41):2793-2867. DOI: 10.1093/eurheartj/ehv316. View

Pillarisetti J, Gopinathannair R, Haney M, Abazid B, Rawasia W, Reddy M . Risk of ventricular tachyarrhythmias following improvement of left ventricular ejection fraction in patients with implantable cardiac defibrillators implanted for primary prevention of sudden cardiac death. J Interv Card Electrophysiol. 2017; 48(3):283-289. DOI: 10.1007/s10840-017-0222-1. View

van Rees J, Borleffs C, de Bie M, Stijnen T, van Erven L, Bax J . Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011; 57(5):556-62. DOI: 10.1016/j.jacc.2010.06.059. View

10.

Roger S, Rosenkaimer S, Hohneck A, Lang S, El-Battrawy I, Rudic B . Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting. BMC Cardiovasc Disord. 2018; 18(1):52. PMC: 5856002. DOI: 10.1186/s12872-018-0790-8. View

11.

Elming M, Nielsen J, Haarbo J, Videbaek L, Korup E, Signorovitch J . Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation. 2017; 136(19):1772-1780. DOI: 10.1161/CIRCULATIONAHA.117.028829. View

12.

Hunt S, Abraham W, Chin M, Feldman A, Francis G, Ganiats T . 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines:.... Circulation. 2009; 119(14):e391-479. DOI: 10.1161/CIRCULATIONAHA.109.192065. View

13.

Wong J, Roberts J, Healey J . The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape. Can J Cardiol. 2021; 37(4):644-654. DOI: 10.1016/j.cjca.2021.01.024. View

14.

McMurray J, Adamopoulos S, Anker S, Auricchio A, Bohm M, Dickstein K . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the.... Eur Heart J. 2012; 33(14):1787-847. DOI: 10.1093/eurheartj/ehs104. View

15.

Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel B, Behr E, Blom N . 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40):3997-4126. DOI: 10.1093/eurheartj/ehac262. View

16.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

17.

Shen L, Jhund P, Petrie M, Claggett B, Barlera S, Cleland J . Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017; 377(1):41-51. DOI: 10.1056/NEJMoa1609758. View

18.

Goh Z, Javed W, Shabi M, Klassen J, Saunderson C, Farley J . Early prediction of left ventricular function improvement in patients with new-onset heart failure and presumed non-ischaemic aetiology. Open Heart. 2023; 10(2). PMC: 10441102. DOI: 10.1136/openhrt-2023-002429. View

19.

Roth G, Poole J, Zaha R, Zhou W, Skinner J, Morden N . Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation. J Am Coll Cardiol. 2016; 67(9):1062-1069. PMC: 4780248. DOI: 10.1016/j.jacc.2015.12.046. View

20.

Radesich C, Cappelletto C, Indennidate C, Perotto M, Lenarda A . Predicting left ventricular functional recovery in ischaemic cardiomyopathy: needs and challenges. Eur Heart J Suppl. 2023; 25(Suppl B):B69-B74. PMC: 10120944. DOI: 10.1093/eurheartjsupp/suad071. View